Current UrologyPub Date : 2026-11-01Epub Date: 2026-04-27DOI: 10.1097/CU9.0000000000000351
Ignacio Gondolesi, Samer Jaber Di Tommaso, Alan I Benvenisty, Ron Shapiro, Sander S Florman, Michael A Palese
{"title":"Clearing the way: Back-table stone removal in renal transplantation.","authors":"Ignacio Gondolesi, Samer Jaber Di Tommaso, Alan I Benvenisty, Ron Shapiro, Sander S Florman, Michael A Palese","doi":"10.1097/CU9.0000000000000351","DOIUrl":"10.1097/CU9.0000000000000351","url":null,"abstract":"","PeriodicalId":39147,"journal":{"name":"Current Urology","volume":"20 6","pages":"405-407"},"PeriodicalIF":2.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13719119/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149300580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The current landscape of bladder-sparing therapies in BCG-refractory high-risk nonmuscle-invasive bladder cancer.","authors":"Yiqing Gu, Wei He, Xiaowen Yu, Changcheng Jiang, Zhensheng Zhang, Chuanliang Xu, Shuxiong Zeng","doi":"10.1097/CU9.0000000000000356","DOIUrl":"10.1097/CU9.0000000000000356","url":null,"abstract":"<p><p>Intravesical Bacillus Calmette-Guérin (BCG) immunotherapy after transurethral resection of bladder tumor has become the first-line treatment for high-risk nonmuscle-invasive bladder cancer. However, disease recurrence or progression occurs in some patients after BCG therapy. Radical cystectomy is the standard treatment for BCG failure; however, it is not suitable for all patients and the development of alternative therapies is crucial. In addition to traditional intravesical chemotherapy (e.g., gemcitabine and docetaxel), new emerging approaches, including modified BCG, immune checkpoint inhibitors, gene therapy, and oncolytic virus therapy, have provided alternative treatment options and improved outcomes for patients.</p>","PeriodicalId":39147,"journal":{"name":"Current Urology","volume":"20 6","pages":"359-367"},"PeriodicalIF":2.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13719127/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149300860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Explainable artificial intelligence in prostate and bladder cancer: A review of imaging, digital pathology, molecular profiling, and clinical data.","authors":"Dimitrios Diamantidis, Georgios Tsakaldimis, Nikolaos Smyrlis, Chousein Chousein, Charalampos Kafalis, Konstantina Foutzitzi, Evangelia Deligeorgiou, Nikolaos Panagiotopoulos, Stavros Lailisidis, Chrysostomos Georgellis, Stavros Giannopoulos, Stilianos Giannakopoulos, Christos Kalaitzis","doi":"10.1097/CU9.0000000000000367","DOIUrl":"10.1097/CU9.0000000000000367","url":null,"abstract":"<p><p>Artificial intelligence (AI) models are increasingly applied across the detection, staging, treatment selection, and surveillance of prostate and bladder cancer. Explainable AI links predictions to identifiable features, spatial regions, or architectural constraints, supporting clinical audit and informed use. This narrative review synthesizes evidence across both cancers in imaging, digital pathology, molecular and liquid-biopsy data, and clinical applications and assesses deployment readiness. Two parallel structured searches of PubMed/MEDLINE were performed, one for each cancer, covering records through November 15, 2025. Eligible studies applied machine or deep learning to a clinical or translational task and included an explainability component. Seventy studies across 4 data domains were included. Imaging was the most active domain. SHapley Additive exPlanations and gradient-weighted class activation mapping confirmed biologically plausible signal localization. Interpretability-by-design in bladder endoscopy embedded explainability without post hoc approximation. Attention heatmaps and probability maps in digital pathology linked model focus to histological features relevant to grading and invasion. Molecular models ranged from post hoc attribution to pathway-constrained architectures; a biologically structured deep neural network in prostate cancer demonstrated how architectural constraints can move explanations toward mechanistic inference. Clinical and electronic medical record-based models constituted the largest group, using SHapley Additive exPlanations for prebiopsy triage, treatment selection, recurrence prediction, and active surveillance. Post hoc explanations and interpretable-by-design models carry different evidentiary weight. Prospective evidence that explainable AI affects clinical decisions is lacking. Translation requires independent validation of fidelity, stability, and usability, prospective reader studies, standardized reporting, and investment in interpretable architectures.</p>","PeriodicalId":39147,"journal":{"name":"Current Urology","volume":"20 6","pages":"332-348"},"PeriodicalIF":2.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13719121/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149300808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Current UrologyPub Date : 2026-11-01Epub Date: 2026-08-25DOI: 10.1097/CU9.0000000000000364
Prosper Akankwasa, John Katongole, Esther Namutosi, Faith Nabushawo, Ahmed Aisha Abdullahi, Jackson Kakooza, Catherine R Lewis, Emmanuel Okurut
{"title":"Urinary incontinence in women: Global burden, clinical realities, and pathways to care.","authors":"Prosper Akankwasa, John Katongole, Esther Namutosi, Faith Nabushawo, Ahmed Aisha Abdullahi, Jackson Kakooza, Catherine R Lewis, Emmanuel Okurut","doi":"10.1097/CU9.0000000000000364","DOIUrl":"10.1097/CU9.0000000000000364","url":null,"abstract":"","PeriodicalId":39147,"journal":{"name":"Current Urology","volume":"20 6","pages":"402-404"},"PeriodicalIF":2.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13719115/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149300871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Current UrologyPub Date : 2026-11-01Epub Date: 2026-09-23DOI: 10.1097/CU9.0000000000000374
Paul M Rival, Jeffrey Jiang, Liang G Qu, Jonathan O'Brien, Paul Gilmore, Niall Corcoran
{"title":"Bipolar androgen therapy in castration-resistant prostate cancer: Biological rationale, clinical evidence, and future directions.","authors":"Paul M Rival, Jeffrey Jiang, Liang G Qu, Jonathan O'Brien, Paul Gilmore, Niall Corcoran","doi":"10.1097/CU9.0000000000000374","DOIUrl":"10.1097/CU9.0000000000000374","url":null,"abstract":"<p><p>Androgen deprivation therapy remains the cornerstone of systemic treatment for advanced prostate cancer. However, progression to castration-resistant prostate cancer (CRPC) is almost inevitable. Supraphysiological androgen exposure can suppress tumor growth in selected biological contexts, a phenomenon termed the \"testosterone paradox.\" Bipolar androgen therapy (BAT), which rapidly cycles between supraphysiological and near-castrate testosterone levels, has emerged as a novel strategy. This narrative review summarizes contemporary biological insights, clinical evidence, and evolving investigational treatment strategies for BAT in CRPC. A structured narrative literature search of Ovid MEDLINE and Embase (January 2009 to August 2025) was conducted. Chronic androgen suppression promotes adaptive androgen receptor (AR) upregulation, creating a potential vulnerability to supraphysiological androgen exposure through multiple mechanisms reviewed in this study. Clinically, BAT has been evaluated in multiple phase I-II studies involving more than 250 men with CRPC. In selected asymptomatic patients enrolled in early-phase studies, BAT demonstrated feasibility and manageable toxicity, with prostate-specific antigen and radiographic responses observed in approximately 25% to 30% of patients. To date, the most consistent clinical signal has been the restoration of sensitivity to subsequent AR pathway inhibition, along with improvements in selected health-related quality-of-life domains. Combination strategies involving AR inhibitors, poly(ADP-ribose) polymerase (PARP) inhibitors, immunotherapy, and other targeted agents are under active investigation, supported by emerging biomarker-driven hypotheses. International guidelines currently classify BAT as investigational, because of the absence of phase III survival data. Bipolar androgen therapy challenges the conventional androgen suppression paradigms in CRPC and remains an investigational therapeutic strategy for CRPC.</p>","PeriodicalId":39147,"journal":{"name":"Current Urology","volume":"20 6","pages":"321-331"},"PeriodicalIF":2.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13719120/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149300913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Current UrologyPub Date : 2026-11-01Epub Date: 2026-09-23DOI: 10.1097/CU9.0000000000000373
Yingzi Qi, Zhiying Xiao, Dongqi Tang, Yao Sun
{"title":"What we receive, what we decline, and what we seek: Lessons from <i>Current Urology</i>.","authors":"Yingzi Qi, Zhiying Xiao, Dongqi Tang, Yao Sun","doi":"10.1097/CU9.0000000000000373","DOIUrl":"10.1097/CU9.0000000000000373","url":null,"abstract":"","PeriodicalId":39147,"journal":{"name":"Current Urology","volume":"20 6","pages":"411-413"},"PeriodicalIF":2.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13719118/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149300865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Current UrologyPub Date : 2026-11-01Epub Date: 2026-03-03DOI: 10.1097/CU9.0000000000000343
Guojing Pei, Yanjie Liang, Wen Zhang, Mengru Kang, Kang Du, Dongqi Tang, Zhen Zhang, Fang Xiao
{"title":"Application of rapidly prepared nonactivated high-efficiency chimeric antigen receptor T cells in the treatment of bladder cancer.","authors":"Guojing Pei, Yanjie Liang, Wen Zhang, Mengru Kang, Kang Du, Dongqi Tang, Zhen Zhang, Fang Xiao","doi":"10.1097/CU9.0000000000000343","DOIUrl":"10.1097/CU9.0000000000000343","url":null,"abstract":"<p><strong>Background: </strong>Chimeric antigen receptor (CAR) T-cell therapy is clinically limited by lentiviral vector dependence, ex vivo activation/expansion requirements, complex processes, high costs, and impaired antitumor functions. For advanced cancer, the long manufacturing cycle of traditional CAR-T cells further compromises the treatment timeliness, creating an urgent need for optimized preparation strategies.</p><p><strong>Materials and methods: </strong>A gene delivery system was constructed using microtubule-associated sequence and nuclear localization signal peptide-modified poly(β-amino ester) nanoparticles, combined with microfluidic technology. Nonactivated primary human T cells were transfected without ex vivo activation. The transfection efficiency, gene expression persistence, and in vitro cytotoxicity against the B7-H3-positive bladder cancer cell line T24 were evaluated.</p><p><strong>Results: </strong>The system achieved gene delivery to nonactivated T cells within 2 to 6 hours, with a transfection efficiency that was 7-fold higher than that of unmodified nanoparticles. Target genes were stably expressed for over 5 days. The resulting CAR-T cells exhibited potent, specific cytotoxicity against T24 cells, avoiding viral vector risks and reducing manufacturing costs.</p><p><strong>Conclusions: </strong>This strategy innovates CAR-T-cell preparation by targeting nonactivated T cells and overcoming traditional bottlenecks. This provides a simpler, faster, cost-effective, and safe approach for adoptive cellular immunotherapy with significant translational value for bladder cancer and other solid tumors.</p>","PeriodicalId":39147,"journal":{"name":"Current Urology","volume":"20 6","pages":"379-391"},"PeriodicalIF":2.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13719117/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149300941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Current UrologyPub Date : 2026-11-01Epub Date: 2026-05-12DOI: 10.1097/CU9.0000000000000355
Yuankang Feng, Shiyue Zhang, Jianqiao Li, Dan Yue, Yong Wang
{"title":"Targeting lipid metabolism to overcome therapeutic resistance in renal cell carcinoma: Mechanisms and emerging strategies.","authors":"Yuankang Feng, Shiyue Zhang, Jianqiao Li, Dan Yue, Yong Wang","doi":"10.1097/CU9.0000000000000355","DOIUrl":"10.1097/CU9.0000000000000355","url":null,"abstract":"<p><p>Renal cell carcinoma (RCC) is a common urological cancer. Despite advances in immunotherapy and targeted therapy, drug resistance profoundly compromises outcomes. Aberrant lipid metabolism critically shapes the tumor microenvironment and fosters resistance via diverse mechanisms, although the precise underlying pathological pathways remain unclear. This review provides current insights and highlights emerging trends to guide future research. Research interest in the role of lipid metabolism in therapeutic resistance in renal cancer has steadily increased over the years. Lipid metabolism influences therapeutic resistance in RCC primarily through the protein kinase B/mechanistic target of rapamycin signaling pathway, ferroptosis, autophagy, synergy with glucose metabolism, and drug efflux mechanisms. Identifying lipid metabolism biomarkers that are predictive of RCC treatment response and multi-integrating multiomics approaches to optimize therapeutic strategies are critical directions for future studies. Targeting lipid metabolism represents a pivotal nexus between targeted therapy and immunotherapy. Elucidating its interplay with programmed cell death pathways, including ferroptosis and autophagy, may help overcome resistance in RCC. However, the reliance on preclinical models limits their clinical translation. This review refines the current knowledge, identifies emerging avenues, and offers guidance for future research.</p>","PeriodicalId":39147,"journal":{"name":"Current Urology","volume":"20 6","pages":"349-358"},"PeriodicalIF":2.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13719126/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149300824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Renal cell carcinoma with venous tumor thrombus in young adults: Distinct clinicopathological features and shorter progression-free survival.","authors":"Shichao Li, Xinlin Peng, Jialong Song, Cheng Peng, Yibo Chen, Kan Liu, Zhuo Jia, Qilong Jiao, Changwei Shi, Zhenze Yang, Manwei Huang, Juping Qi, Xu Zhang, Liangyou Gu, Xin Ma, Qingbo Huang","doi":"10.1097/CU9.0000000000000363","DOIUrl":"10.1097/CU9.0000000000000363","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to characterize the clinicopathological features and survival outcomes of young patients with renal cell carcinoma and venous tumor thrombus (RCC-VTT).</p><p><strong>Materials and methods: </strong>We retrospectively reviewed 468 patients with RCC-VTT who underwent radical nephrectomy and thrombectomy at a high-volume center. Patients were classified as young (≤40 years, n = 43) or older (>40 years, n = 425). Propensity score matching and overlap weighting were used to improve intergroup comparability. Kaplan-Meier analysis and Cox regression were used to evaluate survival outcomes and prognostic associations.</p><p><strong>Results: </strong>Compared with older patients, young patients had larger tumors, more frequent enlarged lymph nodes, more advanced T stages, and greater perioperative transfusion requirements. They also exhibited distinct histological profiles, with higher proportions of papillary RCC and molecularly defined subtypes. Young age was associated with shorter progression-free survival (PFS) in the unadjusted analysis (hazard ratio, 1.79; 95% confidence interval, 1.19-2.70) and remained associated with shorter PFS after accounting for measured clinicopathological characteristics. Across multivariable modeling approaches, young age was consistently retained in the PFS models, together with established prognostic factors, including distant metastasis and nuclear grade.</p><p><strong>Conclusions: </strong>Among patients with RCC-VTT undergoing surgical treatment, young patients exhibited distinct clinicopathological characteristics and shorter PFS. These findings suggest that age-related prognostic differences may not be fully explained by conventional clinicopathological characteristics and warrant further biological investigation.</p>","PeriodicalId":39147,"journal":{"name":"Current Urology","volume":"20 6","pages":"368-378"},"PeriodicalIF":2.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13719122/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149300884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}